We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

DIAGNOSTICA STAGO

Offers a complete system of hemostasis instrumentation and optimized reagent kits for research, as well as for routin... read more Featured Products: More products

Download Mobile App





STAGO sthemO and sthemE Product Ranges Make World Premiere

By LabMedica International staff writers
Posted on 24 May 2023
Print article
Image: Stago unveiled the sthemO 301 and 201 hemostasis analyzers at EuroMedlab 2023 (Photo courtesy of Stago)
Image: Stago unveiled the sthemO 301 and 201 hemostasis analyzers at EuroMedlab 2023 (Photo courtesy of Stago)

Diagnostica Stago (Asnières-sur-Seine, France) is unveiling its new coagulation line - the sthemO and sthemE product ranges - at WorldLab–EuroMedLab Roma 2023.

Leveraging its proficiency in hemostasis, Stago has diversified its product line to incorporate hematology, becoming a multi-specialist in these fields. The company's new "sthem" brand represents a significant leap towards next-generation Stago solutions. Drawing from over 60 years of partnership with coagulation professionals, Stago has introduced sthemO, a fresh line of hemostasis devices and reagents designed to fulfill the evolving demands of laboratories. The sthemO 301, the first analyzer in the sthemO hemostasis series, is a high-throughput, fully automated coagulation analyzer designed for medium to large laboratories and can be integrated into automated tracks. It offers the perfect combination of expertise, performance, and innovation. Also included in the new range of sthemO analyzers by Stago is the sthemO 201. This bench-top analyzer, suitable for smaller laboratories, offers the same level of efficiency and analytical performance as the sthemO 301. Its simplicity and versatility enable laboratories to concentrate on value-added tasks.

The sthemO analyzers are qualitative and/or quantitative automated hemostasis platforms for in vitro diagnostic use by clinical laboratory staff and are to be used with dedicated sthemO reagents and controls. The company has emphasized technological advancement, integrating an increasing number of features into its sthemO coagulation devices to simplify operations for laboratories and patients alike. The sthemO series incorporates immuno-chemiluminescence technology to provide superior analytical performance and an extensive range of tests. Additionally, Stago has developed a unique cuvette design, compatible with all embedded technologies, to provide a highly efficient, user-friendly system.

In order to optimize these two novel systems, Stago has also launched new eSolutions under the sthemE umbrella. The sthemE Manager is designed to facilitate data and information exchange between one or several in vitro diagnostic analyzers and laboratory information systems. This system, encompassing the sthemE Manager and one or more analyzers, is managed by authorized laboratory personnel. sthemE Manager is not intended for use with specific assays.

Related Links:
Diagnostica Stago

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
New
Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Rheumatoid Arthritis Test
Finecare RF Rapid Quantitative Test
New
Gold Member
LEISHMANIA Test
LEISHMANIA ELISA

Print article

Channels

Molecular Diagnostics

view channel
Image: A coronal MRI section shows a high-intensity focused ultrasound lesion in the left thalamus of the brain (Photo courtesy of UT Southwestern Medical Center)

Newly Identified Stroke Biomarkers Pave Way for Blood Tests to Quickly Diagnose Brain Injuries

Each year, nearly 800,000 individuals in the U.S. experience a stroke, which occurs when blood flow to specific areas of the brain is insufficient, causing brain cells to die due to a lack of oxygen.... Read more

Immunology

view channel
Image: The discovery of biomarkers could improve endometrial cancer treatment (Photo courtesy of Mount Sinai)

Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer

Endometrial cancer, which develops in the lining of the uterus, is the most prevalent gynecologic cancer in the United States, affecting over 66,000 women annually. Projections indicate that in 2025, around... Read more

Pathology

view channel
Image: As tumor cells flow through these microfluidic chambers, they are subjected to increasing shear stress and sorted based on their adhesion strength (Photo courtesy of UC San Diego)

Microfluidic Device Assesses Stickiness of Tumor Cells to Predict Cancer Spread

Ductal carcinoma in situ (DCIS), a type of early-stage breast cancer, is often referred to as stage zero breast cancer. In many cases, it remains harmless and does not spread beyond the milk ducts where... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.